COMMUNIQUÉS West-GlobeNewswire

ProMom Rebuilds Its Motherhood App Around What Matters Most Right Now
13/10/2026
Based on a woman's stage and what she has shared, the redesigned app shows what to do next and what to know now, with clinically governed guidance and her data kept private San Francisco, CA, Oct. 13, 2026 (GLOBE [...]
Long Island Surgeon Launches The Robotic Surgeon, a Podcast That Tells Patients the Truth About Robotic Surgery, Including When They Don't Need It
13/10/2026
Dr. Hesham Atwa of Long Island Laparoscopic Doctors partners with TopHealth on a patient-first podcast and video series built on one promise: no sugarcoating and no selling. EAST SETAUKET, N.Y., Oct. 13, 2026 (GLOBE [...]
Euclid Vision Corporation Launches My Euclid™, a Cloud-Based Ortho-K Lens Fitting Platform
13/10/2026
My Euclid connects topography-guided lens fitting, ordering, patient management and consultation support in one cloud-based workflow Key facts of this press release: My Euclid is now available, bringing topography- [...]
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
13/10/2026
NEW YORK and WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Commure and Compassus Bring AI-Powered Referral Automation to Home-Based Care
13/10/2026
MOUNTAIN VIEW, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Commure, the AI-native enterprise healthcare platform, today announced a strategic partnership with Compassus, a leading national provider of integrated home- [...]
Oorja Bio Announces Initiation of ORBIT-IPF Phase 2 Clinical Trial Evaluating ORJ-001 for the Treatment of Idiopathic Pulmonary Fibrosis
13/10/2026
Randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy in a robust, two-part study First-in-class therapeutic targets Alveolar Epithelial Type 2 (AEC2) cells with the aim to halt disease [...]
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
13/10/2026
Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli ™ wholesale unit sales increased 74% [...]
The Mindful CRNA Bootcamp Trains Nurses to Handle the Pressure of CRNA School
13/10/2026
Starting October 21, the live program helps nurses build the inner capacity that CRNA school demands. Founder Amanda Kay, MSN, CRNA, will close it with news about the platform's next chapter. CHICAGO, Oct. 13, 2026 ( [...]
TaiMed Biologics to Present Oral and Poster Presentations on TMB-365 and TMB-365/TMB-380 Combination Therapy at IDWeek 2026
13/10/2026
Company will present on a single-dose escalation study of TMB-365 and on resistance in the context of the long-acting TMB-365 and TMB-380 maintenance regimen in people living with HIV TAIPEI, Taiwan, Oct. 13, 2026 ( [...]
Envisagenics Awarded $2M+ NCI SBIR Grant to Expand AI-Driven RNA Splicing Analysis Capabilities Across Oncology Portfolio
13/10/2026
Funding will advance translational readiness across Envisagenics’ cancer-specific programs for internal development and strategic partnering NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Envisagenics, Inc. , an AI-driven [...]
Rgenta Therapeutics Announces RGT-61159 Poster Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
13/10/2026
WOBURN, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for [...]
De l’océan au bien-être animal : Acadian lance la technologie d’alimentation optimisée Tasco®, conçue pour renforcer la résilience et la productivité
13/10/2026
DARTMOUTH, Nouvelle-Écosse, 13 oct. 2026 (GLOBE NEWSWIRE) -- Acadian Animal Wellness a annoncé aujourd’hui le lancement mondial de la technologie d’alimentation optimisée Tasco® destinée aux produits d’alimentation [...]
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
13/10/2026
Findings highlight ATYR0101’s potential as a transformative therapy for disrupting the process of chronic tissue fibrosis. ATYR0101 is currently undergoing IND-enabling studies and expects to be advanced into the clinic [...]
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
13/10/2026
EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative [...]
MBX Biosciences to Participate in Upcoming November Investor Conferences
13/10/2026
CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel [...]
Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
13/10/2026
SYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced [...]
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
13/10/2026
The Restructuring Program focuses Clinical Genomics on profitability and adds resources in Sterilization and Disinfection Control, Calibration Solutions and Asia LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa [...]
Tenvie Therapeutics Announces First Subject Dosed in Phase 1 Trial of TNV313, Expanding Its Fully CNS-Penetrant NLRP3 Franchise
13/10/2026
Third drug candidate from Tenvie’s product engine to enter clinical development in 2026 TNV313 joins TNV262 to give Tenvie two clinical-stage, fully CNS-penetrant NLRP3 inhibitors, enabling parallel development across [...]
Novastra Therapeutics to Present Initial Phase 1 Data for OAP-101 in Anti–PD-1–Refractory Advanced Melanoma at ESMO Congress 2026
13/10/2026
First clinical data for OAP-101, built on proprietary OmniAntigen™ Platform (OAP) OAP enables systematic immune reprogramming therapy (XIRT™) to overcome resistance of cold solid tumors to current therapies, including [...]

Pages